EMA Withdrawn: Azacitidine Celgene (azacitidine) — Celgene Europe BV

View source ↗

Summary

The EMA has withdrawn the azacitidine product Celgene Europe BV from the market.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia Myeloid Acute
• Leukemia Myelomonocytic Chronic
• Myelodysplastic Syndromes

Drugs mentioned

• Azacitidine Celgene (azacitidine)

Snippet

Status: Withdrawn. Therapeutic area: Myelodysplastic Syndromes;Leukemia, Myelomonocytic, Chronic;Leukemia, Myeloid, Acute. MAH: Celgene Europe BV. Decision date: 21/05/2021